2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Biological activity
Description
Target:
EC50 value: 0.28 uM [1]
Target: β cell proliferation agonist
In Vivo
RIP-DTA mice were fed Dox in the drinking water until the onset of overt diabetes (blood glucose reading >300 mg/dL, typically 4-10 days), at which point Dox treatment was discontinued and treatment with WS6 was initiated (5 mg/kg every other day via intraperitoneal injection). Pharmacokinetic studies with WS6 at 50 mg/kg revealed a CMAX of ～5 μM and T1/2 of ～2 h. Treatment with WS6 caused a progressive reduction of blood glucose over time, starting around 2 weeks.
In Vitro
WS6 induced up to 4% of rat β cells to proliferate, with an EC50 of 0.4 μM. In the same format, WS6 also induced 3% of human β cells to proliferate, with a similar potency to the rat β cells. WS6 induced R7T1 proliferation in dose response, with EC50 value of 0.28 μM, Proliferation of R7T1 cells, which are cultured in suspension and grow as clusters, was apparent by visible inspection.
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Shen W, et al. Small-molecule inducer of β cell proliferation identified by high-throughput screening. J Am Chem Soc. 2013 Feb 6;135(5):1669-72.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
